Unknown

Dataset Information

0

Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.


ABSTRACT: The anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (NB). In NB, ALK overexpression, or point mutations, are associated with poor prognosis and advanced stage disease. Inhibition of ALK kinase activity by small-molecule inhibitors in lung cancers carrying ALK translocations has shown therapeutic potential. However, secondary mutations may occur that, generate tumor resistance to ALK inhibitors. To overcome resistance to ALK inhibitors in NB, we adopted an alternative RNA interference (RNAi)-based therapeutic strategy that is able to knockdown ALK, regardless of its genetic status [mutated, amplified, wild-type (WT)]. NB cell lines, transduced by lentiviral short hairpin RNA (shRNA), showed reduced proliferation and increased apoptosis when ALK was knocked down. In mice, a nanodelivery system for ALK-specific small interfering RNA (siRNA), based on the conjugation of antibodies directed against the NB-selective marker GD(2) to liposomes, showed strong ALK knockdown in vivo in NB cells, which resulted in cell growth arrest, apoptosis, and prolonged survival. ALK knockdown was associated with marked reductions in vascular endothelial growth factor (VEGF) secretion, blood vessel density, and matrix metalloproteinases (MMPs) expression in vivo, suggesting a role for ALK in NB-induced neoangiogenesis and tumor invasion, confirming this gene as a fundamental oncogene in NB.

SUBMITTER: Di Paolo D 

PROVIDER: S-EPMC3242652 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma.

Di Paolo Daniela D   Ambrogio Chiara C   Pastorino Fabio F   Brignole Chiara C   Martinengo Cinzia C   Carosio Roberta R   Loi Monica M   Pagnan Gabriella G   Emionite Laura L   Cilli Michele M   Ribatti Domenico D   Allen Theresa M TM   Chiarle Roberto R   Ponzoni Mirco M   Perri Patrizia P  

Molecular therapy : the journal of the American Society of Gene Therapy 20110809 12


The anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor that is involved in the pathogenesis of different types of human cancers, including neuroblastoma (NB). In NB, ALK overexpression, or point mutations, are associated with poor prognosis and advanced stage disease. Inhibition of ALK kinase activity by small-molecule inhibitors in lung cancers carrying ALK translocations has shown therapeutic potential. However, secondary mutations may occur that, generate tumor resistance to ALK i  ...[more]

Similar Datasets

| S-EPMC3730824 | biostudies-literature
| S-EPMC8776734 | biostudies-literature
| S-EPMC1603453 | biostudies-literature
| S-EPMC4496127 | biostudies-literature
2021-12-31 | E-MTAB-10903 | biostudies-arrayexpress
| S-EPMC9801621 | biostudies-literature
| S-EPMC8508804 | biostudies-literature
| S-EPMC4958954 | biostudies-literature
| S-EPMC3319004 | biostudies-literature
| S-EPMC4564599 | biostudies-literature